BRENTWOOD, Tennessee, 18 de outubro de 2023 /PRNewswire/– A Currax Pharmaceuticals LLC (“Currax”) anunciou hoje os resultados de linha superior de uma análise de resultados de saúde cardiovascular (HOA). Este estudo avaliou a segurança cardiovascular do CONTRAVE®/MYSIMBA®, um medicamento…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.